ZA200201789B - Substituted pyrrolidin-2,3,4-trion-3-oxime drivatives useful as NMDA-receptor antagonists. - Google Patents

Substituted pyrrolidin-2,3,4-trion-3-oxime drivatives useful as NMDA-receptor antagonists.

Info

Publication number
ZA200201789B
ZA200201789B ZA200201789A ZA200201789A ZA200201789B ZA 200201789 B ZA200201789 B ZA 200201789B ZA 200201789 A ZA200201789 A ZA 200201789A ZA 200201789 A ZA200201789 A ZA 200201789A ZA 200201789 B ZA200201789 B ZA 200201789B
Authority
ZA
South Africa
Prior art keywords
drivatives
trion
nmda
oxime
useful
Prior art date
Application number
ZA200201789A
Other languages
English (en)
Inventor
Michael Przewosny
Hans-Dietrich Stachel
Hermann Poschenrieder
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of ZA200201789B publication Critical patent/ZA200201789B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
ZA200201789A 1999-08-06 2002-03-04 Substituted pyrrolidin-2,3,4-trion-3-oxime drivatives useful as NMDA-receptor antagonists. ZA200201789B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19936521A DE19936521A1 (de) 1999-08-06 1999-08-06 Substituierte Pyrrolidin-2,3,4-trion-3-oxim-Derivate

Publications (1)

Publication Number Publication Date
ZA200201789B true ZA200201789B (en) 2003-06-25

Family

ID=7917036

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200201789A ZA200201789B (en) 1999-08-06 2002-03-04 Substituted pyrrolidin-2,3,4-trion-3-oxime drivatives useful as NMDA-receptor antagonists.

Country Status (25)

Country Link
US (1) US6716872B2 (zh)
EP (1) EP1200400B1 (zh)
JP (1) JP2003506436A (zh)
KR (1) KR20020025215A (zh)
CN (1) CN1378531A (zh)
AR (1) AR030678A1 (zh)
AT (1) ATE277901T1 (zh)
AU (1) AU779187B2 (zh)
BR (1) BR0013313A (zh)
CA (1) CA2380973A1 (zh)
CO (1) CO5190692A1 (zh)
DE (2) DE19936521A1 (zh)
ES (1) ES2226876T3 (zh)
HK (1) HK1046404A1 (zh)
HU (1) HUP0202433A3 (zh)
IL (1) IL147978A0 (zh)
MX (1) MXPA02001215A (zh)
NO (1) NO20020578L (zh)
NZ (1) NZ516905A (zh)
PE (1) PE20010381A1 (zh)
PL (1) PL353875A1 (zh)
PT (1) PT1200400E (zh)
SK (1) SK1692002A3 (zh)
WO (1) WO2001010831A1 (zh)
ZA (1) ZA200201789B (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3796692B2 (ja) * 2002-02-13 2006-07-12 農工大ティー・エル・オー株式会社 生物運動動作の観察自動化の方法及び装置、並びに特定の運動動作の定量化装置
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
EP2117540A1 (en) 2007-03-01 2009-11-18 Probiodrug AG New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
SG178953A1 (en) 2009-09-11 2012-04-27 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2832790A (en) * 1954-09-28 1958-04-29 Du Pont 4-negative functionally substituted 2, 3, 5-trichalcogenpyrrolidines, their salts, and methods for preparing them
DE4317651A1 (de) * 1993-05-27 1994-12-01 Hoechst Ag Substituierte Bernsteinsäureimide
GB9418443D0 (en) * 1994-09-13 1994-11-02 Pfizer Ltd Therapeutic agents
DE19732928C2 (de) * 1997-07-31 2000-05-18 Gruenenthal Gmbh Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel

Also Published As

Publication number Publication date
WO2001010831A1 (de) 2001-02-15
HUP0202433A2 (hu) 2002-12-28
US6716872B2 (en) 2004-04-06
EP1200400B1 (de) 2004-09-29
US20030027852A1 (en) 2003-02-06
NO20020578D0 (no) 2002-02-05
EP1200400A1 (de) 2002-05-02
PL353875A1 (en) 2003-12-01
HUP0202433A3 (en) 2003-06-30
AR030678A1 (es) 2003-09-03
CA2380973A1 (en) 2001-02-15
JP2003506436A (ja) 2003-02-18
PT1200400E (pt) 2005-02-28
NZ516905A (en) 2004-07-30
AU779187B2 (en) 2005-01-13
NO20020578L (no) 2002-03-25
AU5986800A (en) 2001-03-05
DE50008020D1 (de) 2004-11-04
PE20010381A1 (es) 2001-05-05
HK1046404A1 (zh) 2003-01-10
IL147978A0 (en) 2002-09-12
MXPA02001215A (es) 2002-07-02
CN1378531A (zh) 2002-11-06
DE19936521A1 (de) 2001-02-15
CO5190692A1 (es) 2002-08-29
KR20020025215A (ko) 2002-04-03
SK1692002A3 (en) 2002-07-02
ES2226876T3 (es) 2005-04-01
ATE277901T1 (de) 2004-10-15
BR0013313A (pt) 2002-04-16

Similar Documents

Publication Publication Date Title
ZA200201269B (en) Toothbrush.
ZA200203768B (en) Toothbrush.
EP1235798A4 (en) PIPERIDINYL SUBSTITUTED IN 1.4 EFFECTIVE AS ANTAGONIST NMDA / NR2B
HK1042488A1 (en) 1-Heterocycle substituted diarylamines.
ZA200107409B (en) Fuel composition.
HK1039330A1 (en) Piperidine derivatives useful as ccr5 antagonists.
ZA200204395B (en) Selective neurokinin antagonists.
MXPA01010670A (es) Composicion desinfectante a base de h2o2, acidos y iones metalicos.
ZA200001591B (en) Polymer compositions.
IL149103A0 (en) 2,4-diaminopyrimidine compounds useful as immunosuppressants
HK1051199A1 (en) New phenylpiperazines.
MXPA03006991A (es) Derivados de piperidina como antagonistas de neurocinina 1.
ZA200201789B (en) Substituted pyrrolidin-2,3,4-trion-3-oxime drivatives useful as NMDA-receptor antagonists.
HK1054848A1 (en) Toothbrush.
HK1042699A1 (en) N-triazolylmethyl-piperazine derivatives as neurokinin receptor antagonists.
MXPA03001783A (es) N-(3,5-dicloro-2-metoxifenil)-4-metoxi-3- piperazin-1 -il -bencenosulfonamida.
AU2673201A (en) Alpha-arylethylpiperazine derivatives as neurokinin antagonists
MXPA02000261A (es) Aminoindanos novedosos.
GB2357283B (en) I.S. Machine
HK1054382A1 (en) Substituted pyrroles.
ZA200005697B (en) Paroxetine compositions.
GB2347421B (en) I.S. machine
GB2357285B (en) I.S. machine
AU6827300A (en) Substituted arylalkylamino-1,3,5-triazines
HUP0204169A3 (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines an